Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy Establish Clinical Development … – Nasdaq
|
Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy Establish Clinical Development …
Nasdaq PLYMOUTH MEETING, Pa. and SAN FRANCISCO, Jan. 09, 2018 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and the Parker Institute for Cancer Immunotherapy have entered into a clinical collaboration agreement that provides for Inovio and the … |
